

Friday November 7<sup>th</sup>, 2008

- 9.00 Inflammatory breast cancer: a special tumor entity?  
Massimo Cristofanilli
- 9.30 Controversies in the management of patients undergoing primary systemic therapy (discussion with audience and expert panel)  
Discussant: V. Guarneri  
Clinical Panel: Filippo Bertoni, Alberto Bottini, Gabriel N. Hortobagyi, Maria Grazia Lazzaretti, Antonio Maiorana, Michael Untch, Giovanni Tazzioli
- Items:
- Muticentric - Multifocal tumors
  - Role of displastic/In situ lesions in defining optimal surgery
  - Management of patients with familial/hereditary B
  - Adjuvant Treatment after PST
  - Radiation therapy after PST
- 10.30 *Coffee Break*
- 11.00 Management of special metastatic sites  
Gabriel N. Hortobagyi
- 11.30 Therapeutic options according to prior adjuvant therapy and molecular subtypes  
Pier Franco Conte
- 12.00 Q&A
- 12.30 *Lunch*
- 13.30 New approaches for HER2 positive disease  
Valentina Guarneri
- 13.50 Anti-angiogenic agents in breast cancer  
Antonio Frassoldati
- 14.10 Q&A
- 14.30 Supportive care and complementary medicine for breast cancer patients  
Matti Aapro
- 15.00 Clinical case discussion in metastatic breast cancer  
Discussants: Carmelo Bengala, Roberto Sabbatini  
Clinical Panel: Matti Aapro, Pier Franco Conte, Massimo Cristofanilli, Antonio Frassoldati, Valentina Guarneri, Gabriel N. Hortobagyi,
- Items:
- hormone refractory bone metastatic disease only
  - sequence of HT in pre and postmenopause
  - CNS progression in HER2 positive diseases
  - locoregional treatment for metastatic breast cancer
  - treatment choice and duration
  - drug rechallenge
  - early prediction of response
- 17.00 Conclusions and final questionnaire